Hepatitis C virus, autoimmunity and lymphoproliferation

Mount Sinai Journal of Medicine

Volumn 67, Issue 2, 2000, Pages 120-132

  Eng, Michael A ^a   Kallemuchikkal, Usha ^a   Gorevic, Peter D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cryoglobulinemia; Hepatitis C virus; Non Hodgkin's lymphoma; Vasculitis

Indexed keywords

AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CASE REPORT; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C VIRUS; HUMAN; LEG ULCER; LUNG INFILTRATE; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; PREVALENCE; SENSORIMOTOR NEUROPATHY; VASCULITIS; VIRUS INFECTION;

AGED; AUTOIMMUNITY; CRYOGLOBULINEMIA; FATAL OUTCOME; FEMALE; HEPATITIS C; HUMANS;

EID: 0034061172     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362.
2. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26 (Suppl 1):15S-20S.
3. Alter MJ, Kruszon-Moran, D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
4. Pereira BJG, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51:981-999.
5. Morales JM, Campistol JM, Andres A, Rodicio JL. Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997; 6:511-515.
6. Koziel MJ. Immunology of viral hepatitis. Am J Med 1996; 100:98-109.
7. Cohen J. The scientific challenge of hepatitis C. Science 1999; 285:26-30.
8. Colombo M. Recent results: The role of hepatitis C virus in hepatocellular carcinoma. Cancer Res 1998; 154:337-344.
9. Colantoni A, Hassanein T, Idilman R, Van Thiel DH. Liver transplantation for chronic viral liver disease. Hepatogastroenterology 1998; 45:1357-1363.
10. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999; 13:1315-1350.
11. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-619.
12. Ferri C, La Civita L, Longombardo G, et al. Mixed cryoglobulinemia: A cross-road between autoimmune and lymphoproliferative disorders. Lupus 1998; 7:275-279.
13. Valentini G, Mantelli A, Persico M, et al. Serological and clinical markers of autoimmune disease in HCV-infected subjects with different disease conditions. Clin Exp Rheumatol 1999; 17:75-79.
14. Levey JM, Bjornsson B, Banner B, et al. Mixed cryoglobulinemia in chronic hepatitis C infection. Medicine 1994; 73:53-67.
15. Tanaka K, Aiyama T, Imai J, et al. Serum cryoglobulin and chronic hepatitis C virus disease among Japanese patients. Am J Gastroenterol 1995; 90:1847-1852.
16. Wong VS, Egner W, Elsey T, et al. Incidence, character and clinical relevance of mixed cryoglobulinemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996; 104:25-31.
17. Kallemuchikkal U, Gorevic PD. Evaluation of cryoglobulins. Arch Pathol Lab Med 1999; 123:119-125.
18. Gorevic PD, Frangione B. Mixed cryoglobulinemia (MC) crossreactive idiotypes: Implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 1991; 28:79-94.
19. Donada C, Crucitti A, Donadon V, et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and Type II or Type III cryoglobulinemia. J Viral Hepat 1998; 5:179-185.
20. Tsai J-F, Jeng J-E, Chang W-Y, et al. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine 1995; 74:136-143.
21. Nomura H, Ogo T, Rikimaru N, et al. Hepatitis C virus-related liver damage is related to cold activation of complement. J Clin Gastroenterol 1997; 25:529-534.
22. Pirisi M, Scott F, Ferraccioli G, et al. Mild sialoadenitis: A common finding in patients with hepatitis C virus infection. Scand J Gastroenterol 1994; 29:940-942.
23. Leroy V, Arvieux J, Jacob MC, et al. Prevalence and significance of anticardiolipin, anti-beta2 glycoprotein I and antiprothrombin antibodies in chronic hepatitis C. Br J Haematol 1998; 101:468-474.
24. Puri V, Bookman A, Yeo E, et al. Antiphospholipid antibody syndrome associated with hepatitis C infection. J Rheumatol 1999; 26:509-510.
25. Wener MH, Johnson RJ, Sasso EH, Gretch DR. Hepatitis C virus and rheumatic disease. J Rheumatol 1996; 23:953-959.
26. Willson RA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997; 92:4-17.
27. McMurray RW, Elbourne K. Hepatitis C virus and autoimmunity. Semin Arthritis Rheum 1997; 26:689-701.
28. Abel G, Zhang Q-X, Agnello V. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 1993; 36:1341-1349.
29. Sawada T, Hirohata S, Inoue T, Ito K. Development of rheumatoid arthritis after hepatitis C virus infection. Arthritis Rheum 1991; 34:1620-1621.
30. Gorevic PD. "Cryopathies." In: Frank MM, Austen KF, Claman HN, Unanue ER, editors. Samter's immunological diseases. 5th ed. V. II, Chapter 52. Boston: Little Brown & Co.; 1994. pp. 951-974.
31. Monteverde A, Rivano MT, Allegra GC, et al. Essential mixed cryoglobulinemia, type II: A manifestation of a low-grade malignant lymphoma Acta Haematol 1988; 79:20-25.
32. Monteverde A, Sabattini E, Poggi S, et al. Bone marrow findings further support the hypothesis that essential mixed cryoglobulinemia type II is characterized by a monoclonal B-cell proliferation. Leuk Lymphoma 1995; 20:119-124.
33. Pozzato, G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection and mixed cryoglobulinemia. Blood 1994; 84:3047-3053.
34. Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol 1994; 88:392-394.
35. Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. BrJ Haematol 1997; 99:475-480.
36. Mangia A, Clemente R, Musto P, et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 1996; 10:1209-1213.
37. Andreone P, Zignego AL, Cursaro C. et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998; 129:294-298.
38. Yoshikawa M, Imazu H, Ueda S, et al. Prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma and multiple myeloma. A report from Japan. J Clin Gastroenterol 1997; 25:713-714.
39. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. Ann Intern Med 1997; 127:423-428.
40. Germanidis G, Haioun C, Pourquier J, et al. Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center. Blood 1999; 93:1778-1779.
41. Paydas S, Kilic B, Sahin B, Bugdayci R. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in southern Turkey. Br J Cancer 1999; 80:1303-1305.
42. Brind AM, Watson JP, Burt A, et al. Non-Hodgkin's lymphoma and hepatitis C virus infection. Leuk Lymphoma 1996; 21:127-130.
43. Thalen DJ, Raemaekers J, Galama J, Cooreman MP. Absence of hepatitis C virus infection in non-Hodgkin's lymphoma. Br J Haematol 1997; 96:880-881.
44. King PD, Wilkes JD, Diaz-Arias AA. Hepatitis C virus infection in non-Hodgkin's lymphoma. Clin Lab Haematol 1998; 20:107-110.
45. Collier JD, Zanke B, Moore M, et al. No association between hepatitis C and B-cell lymphoma. Hepatology 1999; 29:1259-1261.
46. De Vita S, Sansonno D, Gloghini A, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997; 90:776-782.
47. Ascoli V, Lo Coco F, Artini M, et al. Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol 1998; 109:600-609.
48. Vallisa D, Berte R, Rocca A, et al. Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med 1999; 106:556-560.
49. Luppi M, Longo G, Ferrari MG, et al. Additional neoplasms and HCV infection in low-grade lymphoma of the MALT type. Br J Haematol 1996; 94:373-375.
50. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid tissue lymphoma of the stomach. N Engl J Med 1998; 338:804-810.
51. Tkoub EM, Haioun C, Pawlotsky JM, et al. Chronic hepatitis C virus and gastric MALT lymphoma [letter]. Blood 1998; 91:360.
52. Rasul I, Shepherd FA, Kamel-Reid S, et al. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology 1999; 29:543-547.
53. Franzin F, Efremov DG. Pozzato G, et al. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995; 90:548-552.
54. Ivanoski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998; 91:2433-2442
55. Ferri C, Monica M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82:3701-3704.
56. Gabrielli A, Manzin A, Candela M, et al. Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinemia. Clin Exp Immunol 1994; 97:87-93.
57. Navas S, Martin J, Quiroga JA, et al. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol 1998; 72:1640-1646.
58. Zehender G, Meroni L, De Maddalena, C, et al. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells in chronically infected patients. J Infect Dis 1997; 176:1209-1214.
59. Dammacco F, Gatti P, Sansonno D. Hepatitis C virus infection, mixed cryoglobulinemia, and Non-Hodgkin's lymphoma: An emerging picture. Leuk Lymphoma 1998; 31:463-476.
60. Negro F, Levrero M. Does the hepatitis C virus replicate in cells of the hematopoietic lineage? Hepatology 1998; 28:261-264.
61. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-941.
62. Moldvay J, Deny P, Pol S, et al. Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood 1994; 83:269-273.
63. Zignego AL, Ferri C, Giannnini C, et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: Evidence for a pathogenetic role. Arch Virol 1997; 142:545-555.
64. Silvestri F, Barillari G, Fanin R, et al. The genotype of hepatitis C virus in patients with HCV-related B-cell non-Hodgkin's lymphoma. Leukemia 1997; 11:2157-2161.
65. Luppi M, Ferrari MG, Torelli G. Hepatitis C virus genotype distribution in B-cell non-Hodgkin's lymphoma [letter]. Ann Intern Med 1998; 128:602.
66. Sansonno D, De Vita S, Iacobellii AR, et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998; 160:3594-3601.
67. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999; 19:157-169.
68. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996; 226:176-182.
69. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272:10983-10986.
70. Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72:3691-3697.
71. Marusawa H, Hijkata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol 1999; 73:4713-4720.
72. Gorevic PD, Levo Y, Kassab J, et al. Mixed cryoglobulinemia. Clinical aspects and long-term follow-up. Am J Med 1980; 69:287-308.
73. Nemni R, Corbo M, Fazio R, et al. Cryoglobulinemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 1988; 111:541-552.
74. Bonetti B, Invernizzi F, Rizzuto N, et al. T-cell-mediated epineurial vasculitis and humoral-mediated microangiopathy in cryoglobulinemic neuropathy J Neuroimmunol 1997; 73:145-154.
75. Fong T-L, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107:196-199.
76. Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1. Ann Intern Med 1999; 130:226-230.
77. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91:1198-1205.
78. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 1996; 77:2604-2613.
79. Zein NN, Rakela J, Krawitt EL, et al. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity and response to interferon therapy. Ann Intern Med 1996; 125:634-639.
80. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: Patients with normal aminotransferase levels. Hepatology 1997; 26 (Suppl 1):133S-136S.
81. Morita K, Tanaka K, Saito S, et al. Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J Med Virol 1999; 58:359-365.
82. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30:526-530.
83. Minton EJ, Smillie D, Neal KR, et al. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998; 178:39-44.
84. Borden EC, Parkinson D. Interferons: Effectiveness, toxicities and costs. Ann Intern Med 1996; 125:614-616.
85. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999; 53:242-254.
86. Roithinger FX, Allinger S, Kirchgatterer A, et al. A lethal course of chronic hepatitis C, glomerulonephritis and pulmonary vasculitis unresponsive to interferon treatment. Am J Gastroenterol 1995; 90:1006-1008.
87. Kurosaki M, Enomoto N, Nouchi T, et al. Fraction-specific populations of the hypervariable region of the hepatitis C virus in a patient with cryoglobulinemia. J Med Virol 1995; 46:403-408.
88. Farci P, Bukh J, Purcell RH. The quasispecies of hepatitis C virus and the host immune response. Springer Semin Immunopathol 1997; 19:5-26.
89. Siami GA, Siami FS. Cryofiltration apheresis in the United States. Ther Apher 1998 2:228-235.
90. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral induced macrophage production of TNF, IL-1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response. J Immunol 1996; 160:3487-3493.
91. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
92. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-1499.
93. Donada C, Crucitti A, Donadon V, et al. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 1998; 92:2983-2984.